Figure. Estimated Number of Individuals With Fibroblast Growth Factor Receptor 2 (FGFR2) and FGFR3 Alterations Who Could Be Eligible for Off-label Use of Erdafitinib.
GE indicates gastroesophageal.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.